RxDoctor Payments Data

Joel Henderson, MD

Anatomic Pathology · Boston, MANPI 1437165958

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $4,175 of the $6,283 with a category attached, or 66.4%. Every reported general payment came from a single manufacturer, Novartis.

$6,283in general payments, 2019–2025

Across 5 payments — averaging $1256.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$6K
$673,064in research payments, 2019–2025

Across 7 payments — averaging $96,152 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$673K

What the payments were for

  • Consulting fees$2,00032%
  • Speaking & faculty fees$4,17566%
  • Food & beverage$1082%

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis5$6,283

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,283 in reported general payments places this provider in the 80th percentile of 119 anatomic pathology providers in Massachusetts.

See all anatomic pathology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$6,940
Medicare patients
14
Services billed
236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other anatomic pathology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →